Matthew Hill, founder and CEO of Elegen joins a Drug Discovery World webinar to discuss the DNA supply bottleneck in mRNA drug development workflows and how Elegen uses an innovative approach to DNA synthesis to supply biopharma companies rapidly and reliably with long, accurate, dsDNA. With ENFINIA DNA, scientists can eliminate several steps of the traditional mRNA therapy screening and production processes to bring new therapies to market faster.
